Abstract: A method for demulsifying a recovered drilling fluid is disclosed. A recovered drilling fluid is first combined with dilution water and a diethanolamine-based C8-C18 alkanolamide demulsifying agent. The recovered drilling fluid comprises hydrocarbons, a brine having at least 25% total dissolved solids, an emulsifier, and undissolved oil-wetted solids. In a second step, the mixture is separated, or is allowed to separate, into three distinct phases, including a clear oil phase comprising the hydrocarbons, a clear brine phase, and a water-wetted solid phase. Compositions suitable for use as demulsifiers and demulsified compositions are also disclosed. The alkanolamide demulsifying agents enable rapid, clean separation of phases and efficient recovery of 80% or more of the oil phase from the recovered drilling fluid.

Abstract: Provided herein are methods for fatty acid alkanolamide (FAAA) synthesis and isolation from lipid-containing algal biomass, and the products of such methods.

Abstract: The invention relates to the use of sphingosine based compounds, in particular phytosphingosine compounds, in the protection of hydroxyapatite containing materials such as teeth and bone. Such compounds are especially useful in the treatment and prevention of dental caries, dental erosion, dentine hypersensitivity and tartar (dental calculus) formation. Methods and devices are also provided for preventing biofilm formation using sphingosine based compounds. Compositions comprising sphingosine based compounds are also provided.

Abstract: The invention relates to ceramide dimers which are constructed from two ceramide molecules which are crosslinked to each other via their lipophilic end. The ceramide molecules thereby have at least one hydrophilic group at their hydrophilic end for increasing the hydration shell of the dimer. The ceramide dimers according to the invention can be used as pharmaceutical preparation or as cosmetic preparation.

Abstract: A reagent composition for forming fatty acyl amido surfactants is provided which includes an alkali metal or alkaline earth metal salt of an amino compound; a polyol of molecular weight ranging from 76 to 300; and no more than 10% water.

Abstract: Dental compositions are provided comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof: wherein n is an integer from about 2 to about 5.

Abstract: The invention provides derivatives of DEA which have increased potency and hydrolysis resistance as compared to DEA, and compositions thereof, as well as methods of using these derivatives to promote neurogenesis, neurite growth and/or length, and/or promote synaptogenesis.

Abstract: The invention describes novel mono or dihydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.

Abstract: Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.

Abstract: Disclosed is a method involving reacting a deprotonated mono- or dialkanol amine with one or more C4 to about C75 fatty acid monoalcohol esters.

Abstract: This invention relates to certain ceramide-analogues of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; fingolimod). In particular, the present invention relates to pharmaceutical compositions comprising these compounds, as well as processes for their preparation and their use in the treatment of autoimmune conditions, such as multiple sclerosis.

Abstract: Dental compositions are provided comprising a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein n is an integer from about 2 to about 5.

Abstract: The present invention relates to methods for making a fatty acid N-acylalkanolamine having the formula: One of the methods comprises the steps of providing a vinyl ester of a fatty acid having the formula: providing a primary or secondary alkanolamine having the formula: NHR1R2; and reacting the vinyl ester of the fatty acid with the alkanolamine under conditions effective to form the fatty acid N-acylalkanolamine. The other method comprises the steps of providing a fatty acid; purifying the fatty acid; providing a primary or secondary alkanolamine having the formula: NHR1R2; reacting the fatty acid with the alkanolamine under conditions effective to form the fatty acid N-acylalkanolamine; and purifying the formed fatty acid N-acylalkanolamine.

Abstract: The present invention relates to a composition for pharmaceutical or veterinary use, comprising palmitoylethanolamide. In particular, the present invention relates to a pharmaceutical composition for human or veterinary use, containing a therapeutically efficient amount of palmitoylethanolamide in the ultra-micronized form, wherein more than 90% by weight of palmitoylethanolamide has particle sizes lower than 6 microns, together with pharmaceutically acceptable excipients.

Abstract: Disclosed is a method involving reacting a deprotonated mono- or dialkanol amine with one or more C4 to about C75 fatty acid monoalcohol esters.

Abstract: Fatty amide compositions and their derivatives are disclosed. The fatty amides comprise a reaction product of a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives with a primary or secondary amine. Derivatives made by reducing, quaternizing, sulfonating, alkoxylating, sulfating, and sulfitating the fatty amide are also included. The amine reactant can be diethylenetriamine or (2-aminoethyl)ethanolamine, which provide imidazoline amides or N esters, respectively. In one aspect, the ester derivative of the C10-C17 monounsaturated acid or octadecene-1,18-dioic acid is a lower alkyl ester. In other aspects, the ester derivative is a modified triglyceride made by self-metathesis of a natural oil or an unsaturated triglyceride made by cross-metathesis of a natural oil with an olefin. The compositions are valuable for cleaners, fabric treatment, hair conditioning, personal care, antimicrobial compositions, agricultural uses, and oil field applications.

Abstract: The invention concerns new pharmaceutical formulations containing a blend of palmitoyl ethanolamide or PEA and stearoyl ethanolamide or SEA compounds as active principles. The formulation is suitable for oral, parenteral, topical, transdermic, rectal, sublingual, nasal, topical, transdermic, rectal, nasal or sublingual administration, whereby the dosage form of said formulations can be in patches, suppositories, ovules, pessaries, aerosol or spray, emulsions, suspensions, solutions.

Abstract: Dental compositions are provided comprising a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein n is an integer from about 2 to about 5.

Abstract: A surfactant concentrate is provided that includes C8-C22 acyl amido compounds, a polyol and C8-C22 fatty acids. The concentrate is formed via an interesterification reaction between a fatty acid ester and an amino compound or salt thereof in a polyol. The resultant surfactant concentrate will have a Hunter Lab Color Scale value L ranging from 70 to 100.

Abstract: A reagent composition for forming fatty acyl amido surfactants is provided which includes an alkali metal or alkaline earth metal salt of an amino compound; a polyol of molecular weight ranging from 76 to 300; and no more than 10% water.

Abstract: A surfactant concentrate is provided that includes C8-C22 acyl amido compounds, a polyol and C8-C22 fatty acids. The concentrate is formed via an interesterification reaction between a C1-C3 alkyl ester of a C8-C22 fatty acid and an amino compound or salt thereof in a polyol. The resultant surfactant concentrate will have a Hunter Lab Color Scale value L ranging from 70 to 100.

Abstract: A process is provided for preparing C8-C22 acyl amido compounds via reaction in a polyol (molecular weight 76 to 400) of interesterifying a fatty acid ester with an amino compound or salt thereof. The resultant mass of material will have a Hunter Lab Color Scale value L ranging from 70 to 100.

Abstract: The invention relates to hybrid molecules made of two lipids or lipid-analogous compounds which are linked to each other via their lipophilic end. The hybrid molecules thereby have at least one hydrophilic group at their hydrophilic end for increasing the hydration shell of the hybrid molecule. The hybrid molecules according to the invention can be used as pharmaceutical or as a cosmetic preparation.

Abstract: Described herein are the use of peripheral blood derived germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.

Abstract: A therapy for renal diseases, in particular renal diseases which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating of neoplastic diseases. More particularly, the present invention relates to palmitoylethanolamide and diethanolamide of fumaric acid for use in the treatment of renal diseases, in particular those caused by dysmetabolic diseases or by toxic or chemotherapy agents, such as platinum derivatives. Palmitoylethanolamide is used preferably in micronized or ultra-micronized form. Diethanolamide of fumaric acid is used preferably in aqueous solution.

Abstract: The present invention relates to fatty acid alkanolamides or polyolamides containing at least one group Y, where Y stands for CF3—(CH2)a—O—, SF5—, CF3—(CH2)a—S—, CF3CF2S—, [CF3—(CH2)a]2N— or [CF3—(CH2)a]NH—, where a stands for an integer selected from the range from 0 to 5, or formula (I), where Rf stands for CF3—(CH2)r—, CF3—(CH2)r—O—, CF3—(CH2)r—S—, CF3CF2—S—, SF5—(CH2)r— or [CF3—(CH2)r]2N—, [CF3—(CH2)r]NH— or (CF3)2N—(CH2)r—, B stands for a single bond, O, NH, NR, CH2, C(O)—O, C(O), S, CH2—O, O—C(O), N—C(O), C(O)—N, O—C(O)—N, N—C(O)—N, O—SO2 or SO2—O, R stands for alkyl having 1 to 4 C atoms, b stands for 0 or 1 and c stands for 0 or 1, q stands for 0 or 1, where at least one radical from b and q stands for 1, and r stands for 0, 1, 2, 3, 4 or 5, to processes for the preparation of these compounds, and to uses of these surface-active compounds.

Abstract: The present invention relates to novel fatty acid derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as agents for the treatment of obesity and related disorders, and for improving cognition.

Abstract: The invention provides methods for using fatty acid alkanolamides for reducing lipid absorption from the intestine of an animal. Reducing lipid absorption results in fewer lipids available for an animal to convert to body fat. Converting fewer lipids to body fat means that the animal reduces body fat, body weight, and/or body weight gain when consuming an equivalent amount of lipids without the fatty acid alkanolamides.

Abstract: A personal care composition comprising a eutectic mixture, the eutectic mixture comprising a CB receptor activating agent, in which the CB receptor is preferably palmitoylethanolamide. A method of mitigating scalp itch.

Abstract: The present invention relates to the use of vanilloid receptor (VR) antagonists, and more particularly vanilloid receptor 1 (VR1) antagonist, as analgesics in the treatment and/or prohylaxis of cnidaria envenomations.

Abstract: The present invention relates to a process for the manufacture of alkanolamide containing compositions, and more particularly to a process of reacting a fatty acid and diethanolamine (DEA) which result in the formation of low levels of undesirable by products, particularly of bis-hydroxyethyl piperazine (BHEP).

Abstract: The present invention discloses a composition for topical use comprising a free sphingoid base and a ceramide. The compositions of the invention are suitable for application to skin conditions associated with an impaired barrier function, in particular to skin conditions further associated with a deranged regulation of cell growth and differentiation, an inflammatory condition and/or an infectious state.

Abstract: The present invention relates to a pseudoceramide represented by the following formula (I) and a cosmetic composition comprising the same: wherein Z represents —OH and Y represents —OH, ?with the proviso that X is Z represents —OH and X represents —OH, with the proviso that Y is Y represents —OH and X represents —OH, with the proviso that Z is R represents a linear or branched, saturated or unsaturated aliphatic hydrocarbon group; and when substituted, R has one or more —OH groups.

Abstract: The present invention is directed to compositions comprising lysophosphatidic acid analogs and methods of using such analogs as agonist or antagonists of LPA receptor activity. In addition the invention is directed to LPA receptor agonists that vary in the degree of selectivity at individual LPA receptors (i.e. LPA1, LPA2 and LPA3). More particularly the present invention is directed to LPA analogs wherein the glycerol is replaced with ethanolamine and a variety of substitutions have been linked at the second carbon atom.

Abstract: The present invention provides a basic amino acid derivative represented by the formula (1): The present invention also provides a method of making a gelled product by employing the aforementioned compound, as well as a gel, perfumery, and/or cosmetic containing the same.

Abstract: A inhibitor of sphingolipids synthesis comprising a compound represented by general formula A. Desirably, a novel inhibitor of sphingolipids synthesis comprising (1R, 3R) N-(3-hydroxy-1-hydroxymethyl-3-phenylpropyl) alkaneamide, wherein carbon number of alkanoyl group is 8-16. (in the formula, X is an aliphatic alkyl group, desirably is an aliphatic alkyl group having 7 to 15 carbon atoms).

Abstract: A process for preparing a composition comprising a mixture with ester and amine function in the form of ester-amines, amines, salts of amines, monoglycerides and diglycerides all derived from monomeric, dimeric, trimeric, and/or tetrameric fatty acids contained in polymerized polyunsaturated oil comprising: (a) polymerizing a polyunsaturated vegetable or animal oil to form a polymerized oil, (b) treating the polymerized oil with water vapor, and (c) reacting the polymerized oil with an excess of at least one compound containing at least one hydroxyl function and at least one tertiary amine function, optionally in the presence of a catalyst. Said methods further comprise adding the compositions to an oil effluent as dispersing agents for hydrates.

Abstract: In order to manufacture a composition mainly containing compounds with ester and amide functions, in particular in the form of ester-amides, as well as compounds with amine functions, such as ester-amines, the salts of amines, monoglycerides and diglycerides, formed from monomeric, dimeric, trimeric and/or tetrameric fatty acids contained in a polymerized polyunsaturated oil, a process is implemented which comprises the following stages: a) use (or preparation) of a polymerized oil by polymerization of a polyunsaturated vegetable or animal oil; b) treatment of said polymerized oil by entrainment with water vapor; and c) reaction of the polymerized oil thus treated with an excess of at least one aminoalcohol, in the presence or not of a catalyst. This composition can be used as an emulsifying and dispersing surfactant, in particular as an additive for dispersing hydrates in oil effluents.

Abstract: Compounds of formula I in which R1 denotes hydrogen or methyl R2 denotes lower straight-chained or branched alkyl with 1 to 10 carbon atoms R3 denotes hydrogen or lower alkyl n denotes 0-12 R4 denotes alkyl, alkenyl or alkinyl with 6 to 24 carbon atoms, processes for the production thereof as well as pharmaceutical agents containing these compounds for the treatment of osteoporosis.

Abstract: Fatty acid derivatives based on epoxidized unsaturated fatty acid esters or triglycerides and reacted with amines such as hydroxy- and/or amino-substituted hydrophilic amines or amino acids and/or with alkanols or with water on the epoxy group and/or the carboxylic ester groups are described. These fatty amides are suitable as surfactants in detergents and cleaners.

Abstract: The invention relates to surfactant-containing formulations which comprise, as surfactant, an N-(3-dialkylamino)propyl-N-polyhydroxyalkylcarboxamide of the formula where R is an aliphatic radical having from 8 to 24 carbon atoms, R1 and R2, which are identical or different, are alkyl groups having from 1 to 4 carbon atoms or hydroxyalkyl groups having from 2 to 4 carbon atoms, and Z is a linear polyhydroxyhydrocarbon radical having at least 3 OH groups, which may also be alkoxylated, and also to their acid addition products. The surfactant-containing formulations are used in industrial and standard household surfactant compositions.

Abstract: The following are described herein: a composition that consists of a mixture that comprises at least amides, amines, ester-amides, ester-amines, amine salts and monoglycerides, that are all derived from monomeric, dimeric, trimeric and/or tetrameric fatty acids; a process for the production of said composition which comprises the transamidification reaction of a polyunsaturated vegetable oil that is polymerized thermally, with an excess of at least one amino alcohol, which may or may not be in the presence of a catalyst; and the uses of this composition particularly as an emulsifying agent that allow it, depending on the nature of the oil, to form an oil-in-water or water-in-oil emulsion, as a solid-dispersing agent, or as an agent for the stabilization of foams in a liquid or an emulsion.

Abstract: Disclosed herein is a ceramide-like compound having properties of the natural ceramides, and a method for producing the same, and a cosmetic composition containing the same as a active ingredient.

Abstract: The invention relates to high-foaming zwitterionic and anionic surfactants which are prepared by sulfation of N,N-dialkylaminoalkyl-sugar amides, preferably using gaseous sulfur trioxide. The invention furthermore relates to compositions which comprise known surfactants and suitable solvents, in addition to the novel active compounds. The novel surfactants are particularly suitable for detergents and cosmetic formulations.

Abstract: Novel phytosphingosine-based analogs of ceramide I, methods for the preparation of these novel compounds, cosmetic and pharmaceutical compositions containing such compounds, and methods for the use thereof are described.

Abstract: The present invention relates to compounds corresponding to the formula: ##STR1## the compounds being in the form of mixtures of isomers at least on the amino alcohol part of the said formula (I). The invention also relates to a process for their preparation and their use, in particular for the treatment and care of the skin, the hair, the nails and the eyelashes in cosmetics or in dermatology.

Abstract: A novel, salt-free monoamphopropionate amphoteric surfactant is prepared in yields of from 75% to 80%, from a reaction comprising an imidazoline and a mixture of acrylic acid and sodium acrylate in an aqueous medium. The acrylic acid/sodium acrylate mixture is comprised of the two components in a range of molar ratios of from about 1:6 to about 1:3, respectively, and by replacing methyl acrylate, the reaction does away with the production of methanol which is an unwanted, hazardous and toxic byproduct. The imidazoline reacts in amounts in excess of 90% resulting in the highly pure yields and any left over unreacted acrylic acid can be easily removed by treating it with sodium bisulfate.

Abstract: An N-alkylpolyhydroxyamine salt of an n-6 or n-3 essential fatty acid (EFA) that is beyond the 6-desaturation step, or of any polyunsaturated fatty acid, other than those belonging to the n-6 and n-3 series, having 16 to 26 carbon atoms and up to six double bonds, the double bonds being in the cis or trans configuration, the salt being formed with the fatty acid either as such or in the form of a covalent derivative, through the carboxyl group, of a bifunctional compound itself having a free acid function.

Abstract: The present invention concerns aqueous surfactant composition comprising poly hydroxy fatty acid amides of formula (A), ##STR1## wherein R.sup.2 is C.sub.11 -C.sub.19 alkyl, alkenyl or mixtures thereof, Z is a polyhydroxyhydrocarbyl moiety having a linear hydrocarbyl chain with at least 3 hydroxyls directly connected to the chain; and in a part of the total amide surfactant (a) R.sup.1 is a methyl group and in the remainder of the total amide surfactant (b) R.sup.1 is an alkyl group with from 3 to 8 carbon atoms; said composition further comprising (c) from 0% to 15% by weight of an organic solvent; wherein the ratio of N-methyl poly hydroxy fatty acid amide (a) to N-alkyl (C.sub.3 -C.sub.8) polyhydroxy fatty acid amide (b), is from 25:1 to 1:1.

Abstract: The ceramides according to the invention are compounds corresponding to the formula: ##STR1## in which: R.sub.1 is a C.sub.11 to C.sub.21 alkyl or alkenyl radical; R.sub.2 is a linear or branched C.sub.1 to C.sub.29 hydroxyalkyl radical or a C.sub.7 to C.sub.29 hydroxyaralkyl radical, these compounds being in the form of a racemic mixture of the erythro and threo diastereoisomers for the aminodiol part ##STR2## in erythro:threo ratios of from 85:15 to 20:80. Application to cosmetic and dermopharmaceutical compositions.